-
Mashup Score: 0How I diagnose and treat neonatal thrombocytopenia - 10 month(s) ago
Using illustrative cases, Stanworth and Mumford explore the current thinking about how best to diagnose and, when appropriate, treat thrombocytopenia in neonate
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 72023 Hematology Review Series - 10 month(s) ago
2023 Hematology Review Series
Source: academy.hematology.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us for this week's Hematology Review Series study session! Discuss all things #thrombocytopenia TONIGHT with Drs. Cindy Neunert & Theodore Warkentin 🤓🩸 Register now: https://t.co/68RHQrXe6a #MedEd #MedTwitter https://t.co/fVSI4OtKO6
-
-
Mashup Score: 0Intermittent Dosing Strategy Helps Thrombocytopenia Related to MDM2 Inhibitor Milademetan - 12 month(s) ago
Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Through an intermittent dosing schedule, thrombocytopenia related to treatments with the MDM2 inhibitor milademetan in patients with sarcomas, and other solid tumors, may be mitigated #oncology #nursing #thrombocytopenia https://t.co/AeE89JeqiD https://t.co/9WHIKXwoMq
-
-
Mashup Score: 0Intermittent Dosing Strategy Helps Thrombocytopenia Related to MDM2 Inhibitor Milademetan - 1 year(s) ago
Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Through an intermittent dosing schedule, thrombocytopenia related to treatments with the MDM2 inhibitor milademetan in patients with sarcomas and other solid tumors, may be mitigated #oncology #nursing #thrombocytopenia https://t.co/umyvDEWZOw
-
-
Mashup Score: 0Intermittent Dosing Strategy Helps Thrombocytopenia Related to MDM2 Inhibitor Milademetan - 1 year(s) ago
Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Intermittent Dosing Strategy Helps Thrombocytopenia Related to MDM2 Inhibitor Milademetan #oncology #nursing #thrombocytopenia https://t.co/MUjmYi87UC
-
-
Mashup Score: 0
A novel machine-learning model has been developed to diagnose heparin-induced thrombocytopenia, which may reduce misdiagnosis.
Source: European Medical JournalCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A NOVEL, accurate, and user-friendly machine learning model has been developed to diagnose heparin-induced thrombocytopenia (HIT), which may reduce misdiagnosis. Learn more: https://t.co/J3FMm7ImGm #machinelearning #thrombocytopenia #hematology
-
-
Mashup Score: 0Making a Diagnosis of Immune Thrombocytopenia - 1 year(s) ago
Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Opening their discussion on immune #thrombocytopenia, expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations. #oncology https://t.co/3LYlBTeY1D
-
-
Mashup Score: 0ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia - 1 year(s) ago
Karnes and colleagues report on the results of a genome-wide association study to find predictors of heparin-induced thrombocytopenia, comparing patients with a
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#ABO O blood group as a risk factor for #Platelet reactivity in #heparin-induced #thrombocytopenia Fascinating observation with some pathophysiology biology to go along with their claim! 👉https://t.co/fdRYS3FC9q @UAZPharmacy #Hemostasis https://t.co/yuMrFpVIIK
-
-
Mashup Score: 0Thrombocytopenia: Evaluation and Management - 1 year(s) ago
Thrombocytopenia is a platelet count of less than 150 × 103 per μL and can occur from decreased platelet production, increased destruction, splenic sequestration, or dilution or clumping. Patients with a platelet count greater than 50 × 103 per μL are generally asymptomatic. Patients with platelet counts between 20 and 50 × 103 per μL may have mild skin manifestations such as petechiae, purpura,…
Source: www.aafp.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
It's there in your inbox: the results from a complete blood count showing thrombocytopenia. But not to worry. We have an algorithm for that! https://t.co/SXEvgv7e5C - @LilyWhiteMD #familymedicine #thrombocytopenia https://t.co/ooEh9HaClD
-
-
Mashup Score: 0Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial - 1 year(s) ago
The antifibrinolytic agent tranexamic acid (TXA) is often used to prevent bleeding in patients with hemorrhagic disorders or platelet dysfunction, and there has
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Prophylactic #TranexamicAcid in patients with hematologic #Malignancy: a placebo-controlled, #RCT For patients with hematologic malignancy, platelets <30k, TXA did not help prevent bleeding! 👉https://t.co/ld2dtIvwCz @TGernsheimer @TriulziDarrell #TXA #Thrombocytopenia https://t.co/mxIc5FWcO0
-
How I diagnose and treat #neonatal #thrombocytopenia 👉https://t.co/zZ7yydZNSF @BloodJournal @SimonStanworth #LifeThreatening https://t.co/p9nIIHynro